Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers

Fig. 1

A combined approach for individualised prediction of endocrine treatment response. Profiling of biopsy samples during neoadjuvant drug treatment may help to match drugs to patients and to predict treatment response. Neoadjuvant assessment should be combined with long-term follow-up of individual tumour changes acquired during treatment via non-invasive (liquid biopsy) sampling. Profiling circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) can be used to monitor continuous benefit from adjuvant treatment and to detect disease progression. In future practice, a combination of these approaches with predictive biomarkers would provide a more accurate prediction of endocrine therapy response

Back to article page